168 related articles for article (PubMed ID: 22249693)
1. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.
Renfrow JJ; Detroye A; Chan M; Tatter S; Ellis T; McMullen K; Johnson A; Mott R; Lesser GJ
J Neurooncol; 2012 May; 107(3):659-63. PubMed ID: 22249693
[TBL] [Abstract][Full Text] [Related]
2. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.
Chamberlain MC
J Neurooncol; 2014 May; 118(1):155-62. PubMed ID: 24584709
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Weidmann E; Kim SZ; Rost A; Schuppert H; Seipelt G; Hoelzer D; Mitrou PS
Ann Oncol; 2002 Aug; 13(8):1285-9. PubMed ID: 12181253
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
Gil L; Kazmierczak M; Kroll-Balcerzak R; Komarnicki M
Med Oncol; 2014 May; 31(5):944. PubMed ID: 24752517
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.
Plosker GL; Carter NJ
Drugs; 2008; 68(18):2645-60. PubMed ID: 19093705
[TBL] [Abstract][Full Text] [Related]
6. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Rummel MJ; Mitrou PS; Hoelzer D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.
van der Jagt R
Expert Rev Hematol; 2013 Oct; 6(5):525-37. PubMed ID: 24125522
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine: inadequate or outdated data.
Prescrire Int; 2012 Mar; 21(125):64. PubMed ID: 22428184
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Garnock-Jones KP
Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy with single agent bendamustine for recurrent glioblastoma.
Chamberlain MC; Johnston SK
J Neurooncol; 2011 Dec; 105(3):523-30. PubMed ID: 21626071
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
Hoy SM
Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.
Heider A; Niederle N
Anticancer Drugs; 2001 Oct; 12(9):725-9. PubMed ID: 11593053
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
[No Abstract] [Full Text] [Related]
17. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
